A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including Diffuse Large B-Cell Lymphoma
Monday, December 11, 2023 BiopharmaWatch Research 1 min read
Key Takeaway: Nurix is initiating a first-in-human Phase 1 trial of NX-1607, an oral CBL-B inhibitor, aimed at treating patients with advanced malignancies, including diffuse large B-cell lymphoma. This trial represents a significant step in the development of innovative cancer therapies. The company is committed to leveraging scientific insights for breakthrough treatments.
Price reaction · baseline $8.6 (2023-12-08 close) · hit pre-market · 1 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
-2.2%
Market Sentiment Analysis
POSITIVE FACTORS
First-in-human trial indicates progress in cancer treatment.
NX-1607 is a novel oral CBL-B inhibitor.
Focus on advanced malignancies shows targeted approach.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is NX-1607?
NX-1607 is a first-in-class oral CBL-B inhibitor developed for cancer treatment.
What type of trial is being conducted for NX-1607?
A first-in-human Phase 1 trial is being conducted for NX-1607.
What conditions does NX-1607 target?
NX-1607 targets advanced malignancies, including diffuse large B-cell lymphoma.
Who is conducting the NX-1607 trial?
The trial is being conducted by Nurix, a biopharmaceutical company.